The surviving sepsis campaign: A history and a perspective

Surgical Infections

Volumn 11, Issue 3, 2010, Pages 275-281

  Marshall, John C ^a   Dellinger, R Phillip ^b   Levy, Mitchell ^c  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY   (United States)

^c RHODE ISLAND HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL TRIAL; EVIDENCE BASED MEDICINE; EVIDENCE BASED PRACTICE; HEALTH CARE ORGANIZATION; HEALTH PROGRAM; HUMAN; INTENSIVE CARE; MEDICAL SOCIETY; NORTH AMERICA; PRACTICE GUIDELINE; PRIORITY JOURNAL; RESUSCITATION; REVIEW; SEPSIS; SEPTIC SHOCK; SOUTH AMERICA; SURVIVAL; SURVIVING SEPSIS CAMPAIGN; EUROPE; FACTUAL DATABASE; MORTALITY; SHOCK, SEPTIC;

DATABASES, FACTUAL; EUROPE; HUMANS; NORTH AMERICA; PRACTICE GUIDELINES AS TOPIC; SEPSIS; SHOCK, SEPTIC; SOUTH AMERICA;

EID: 77954892620     PISSN: 10962964     EISSN: None     Source Type: Journal    
DOI: 10.1089/sur.2010.024     Document Type: Review

References (44)

1. Bone RC Balk RA Cerra FB et al.; ACCP=SCCM Consensus Conference. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Chest 1992;101:1644-1655.
2. Levy MM, Fink M, Marshall JC, et al. 2001 SCCM= ESICM=ACCP=ATS=SIS International Sepsis Definitions Conference. Crit Care Med 2003;34:1250-1256.
3. Angus DC, Linde-Zwirble WT, Lidicker J, et al. Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001;29:1303-1310.
4. Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 2003;348:1546-1554.
5. Lown B, Fakhro AM, Hood WB Jr., Thorn GW. The coronary care unit: New perspectives and directions. JAMA 1967; 199:188-198.
6. Montalescot G, Barragan P, Wittenberg O, et al. Platelet glycoprotein IIb=IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med 2001;344:1895-1903.
7. Mehran R, Lansky AJ, Witzenbichler B, et al. Bivalirudin in patients undergoing primary angioplasty for acute myocar-dial infarction (HORIZONS-AMI): 1-Year results of a randomised controlled trial. Lancet 2009;374:1149-1159.
8. Antman EM, Morrow DA, McCabe CH, et al. Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction. N Engl J Med 2006; 354:1477-1488.
9. Michalek SM, Moore RN, McGhee JR, et al. The primary role of lymphoreticular cells in the mediation of host responses to bacterial endotoxin. J Infect Dis 1980;141:55-63.
10. Tracey KJ, Fong Y, Hesse DG, et al. Anti-cachectin=TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature 1987;330:662-664.
11. Marshall JC. Such stuff as dreams are made on: Mediator-targeted therapy in sepsis. Nature Rev Drug Disc 2003;2: 391-405.
12. Abraham E, Anzueto A, Gutierrez G, et al. Double-blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock. Lancet 1998;351:929-933.
13. Cook DJ, Guyatt GH, Laupacis A, et al. Clinical recommendations using levels of evidence for antithrombotic agents. Chest 1995;108(4 Suppl):227S-230S.
14. Jimenez MF, Marshall JC. Source control in the management of sepsis. Intensive Care Med 2001;27Suppl 1:S49-S62.
15. Brower RG, Matthay MA, Morris A, et al. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. N Engl J Med 2000;342:1301-1308.
16. Hebert PC, Wells G, Blajchman MA, et al. A multicentre randomized controlled clinical trial of transfusion requirements in critical care. N Engl J Med 1999;340:409-417.
17. Rivers E, Nguyen B, Havstad S, et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 2001;345:1368-1377.
18. Van den Berghe G, Wouters P, et al. Intensive insulin therapy in the surgical intensive care unit. N Engl J Med 2001; 345:1359-1367.
19. Bernard GR, Vincent J-L, Laterre PF, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001;344:699-709.
20. Annane D, Sebille V, Charpentier C, et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 2002;288:862-871.
21. Poeze M, Ramsay G, Gerlach H, et al. An international sepsis survey: A study of doctor's knowledge and perception about sepsis. Crit Care 2004;8:R409-R413.
22. Dellinger RP, Carlet JM, Masur H, et al. Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Crit Care Med 2004;32:858-873.
23. Marshall JC, Maier RV, Jimenez M, Dellinger EP. Source control in the management of severe sepsis and septic Marshall JC, Maier RV, Jimenez M, Dellinger EP. Source control in the management of severe sepsis and septicshock: An evidence-based review. Crit Care Med 2004; 32(11Suppl):S513-S526.
24. Berwick DM, Calkins DR, McCannon CJ, Hackbarth AD. The 100,000 Lives Campaign: Setting a goal and a deadline for improving health care quality. JAMA 2006;295:324-327.
25. Pronovost P, Needham D, Berenholtz S, et al. An intervention to decrease catheter-related bloodstream infections in the ICU. N Engl J Med 2006;355:2725-2732.
26. Resar R, Pronovost P, Haraden C, et al. Using a bundle approach to improve ventilator care processes and reduce ventilator-associated pneumonia. Jt Comm J Qual Patient Saf 2005;31:243-248.
27. Eichacker PQ, Natanson C, Danner RL. Surviving Sepsis: Practice guidelines, marketing campaigns, and Eli Lilly. N Engl J Med 2006;355:1640-1642.
28. Wiedermann CJ. Bioethics, the Surviving Sepsis Campaign, and the industry. Wien Klin Wochenschr 2005;117:442-444.
29. Fletcher SJ, Quinn AC. The Surviving Sepsis Campaign and sepsis care bundles: Substance or sophistry? Anaesthesia 2006;61:313-315.
30. Barie PS. An opinion too far\The campaign against the Surviving Sepsis Campaign. Surg Infect 2006;7:485-488.
31. Durbin CG Jr. Is industry guiding the sepsis guidelines? A perspective. Crit Care Med 2007;35:689-691.
32. Wiedermann CJ. When a single pivotal trial should not be enough: The case of drotrecogin-alfa (activated). Intensive Care Med 2006;32:604-1602
33. Eichacker PQ, Natanson C. Recombinant human activated protein C in sepsis: Inconsistent trial results, an unclear mechanism of action, and safety concerns resulted in labeling restrictions and the need for Phase IV trials. Crit Care Med 2003;31(1 Suppl):S94-S96.
34. Dellinger RP, Levy MM, Carlet JM, et al. Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 2008;36: 296-327.
35. Guyatt G, Schunemann HJ, Cook D, et al. Applying the grades of recommendation for antithrombotic and throm-bolytic therapy: The Seventh ACCP Conference on Antith-rombotic and Thrombolytic Therapy. Chest 2004;126(3 Suppl):179S-187S.
36. Jaeschke R, Guyatt GH, Dellinger P, et al. Use of GRADE grid to reach decisions on clinical practice guidelines when consensus is elusive. BMJ 2008;337:a744.
37. Silvestri L, Van Saene HK, de la Cal MA, et al. Surviving Sepsis Campaign needed consensus to exclude selective decontamination of the digestive tract. Crit Care Med 2008;36:2716-2717.
38. Hicks P, Cooper DJ, Webb S, et al. The Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock: 2008: An assessment by the Australian and New Zealand Intensive Care Society. An-aesth Intensive Care 2008;36:149-151.
39. Gao F, Melody T, Daniels DF, et al. The impact of compliance with 6-hour and 24-hour sepsis bundles on hospital mortality in patients with severe sepsis: A prospective observational study. Crit Care 2005;9:R764-R770.
40. Pestana D, Espinosa E, Sanguesa-Molina JR, et al. Compliance with a sepsis bundle and its effect on intensive care unit mortality in surgical septic shock patients. J Trauma 2010 E-pub ahead of print. Feb 3.
41. Ferrer R, Artigas A, Levy MM, et al. Improvement in process of care and outcome after a multicenter severe sepsis educational program in Spain. JAMA 2008;299:2294-2303.
42. Levy MM, Dellinger RP, Townsend SR, et al. The Surviving Sepsis Campaign: Results of an international guideline-based performance improvement program targeting severe sepsis. Crit Care Med 2010;38:367-374.
43. Sprung CL, Annane D, Keh D, et al. Hydrocortisone therapy for patients with septic shock. N Engl J Med 2008;358:111-124.
44. Finfer S, Chittock DR, Su SY, et al. Intensive versus conventional glucose control in critically ill patients. N Engl J Med 2009;360:1283-1297.